Suggestions
Jill Hagenkord
Molecular Genetic Pathologist
Jill Hagenkord, MD, FCAP is a board-certified pathologist with subspecialty boards in molecular genetic pathology.1 She currently serves as the Chief Medical Officer (CMO) of Optum Genomics, a position she has held since May 2020.4
Dr. Hagenkord has an extensive background in genetics and healthcare technology. She received her M.D. from Stanford University School of Medicine in 1999 and completed her residency training at the University of California at San Francisco and the University of Iowa.1 She also pursued fellowships at the University of Pittsburgh Medical Center in Molecular Genetic Pathology and Pathology/Oncology Informatics.14
Throughout her career, Dr. Hagenkord has held several prominent positions in the genomics and healthcare technology industry:
- CMO at 23andMe (2014-2016)4
- CMO at Color Genomics (2016-2019)4
- CMO at Invitae and Complete Genomics3
In her current role at Optum Genomics, Dr. Hagenkord is involved in health product strategy, strategic business partnerships, regulatory strategy, and the development of provider and patient support tools.1 She also serves as a liaison to medical professional societies.1
Dr. Hagenkord is known for her entrepreneurial approach to medicine and her expertise in bridging the gap between technology and healthcare.2 Her experience spans from founding her own diagnostics company, iKaryo Diagnostics, to working with various health tech startups and major corporations.24
Highlights
Optum Genomics (OGx) is looking for individuals who can support utilization management (UM) programs for Oncology Molecular Testing in a Medicare Advantage population on a consulting basis. We anticipate 5-10 hours per week, but could potentially be more depending on case load and number of consultants available. The primary responsibilities are to provide support and consulting / advisory services in Oncology Molecular Pathology for one or more organizations within the United Healthcare umbrella. These individuals require strong knowledge of current molecular tests and their clinical utility as well as intricacies of Medicare coverage policies (local and national) for oncology tests. These individuals should also have knowledge of CPT coding (e.g., for the aforementioned molecular tests). Detailed activities for this consulting support are: Perform case review utilization management requests for tests within the prior authorization list of each organization Provide recommendation based on coverage and medical necessity Collaborate with key organization staff (e.g., coordinators, nurses, medical directors) and providers to ensure appropriate test utilization Participate in training program for staff on background details, clinical scenario(s), coverage criteria, required documentation, and other protocols for relevant genetic tests Optum Genomics is an organization within the UnitedHealth Group (UHG) that is focused on unlocking the promise of precision medicine. One of the services that OGx currently offers is embedding Molecular Diagnostics clinical expertise (Subject Matter Experts = SMEs) to the Utilization Management (UM) teams for providing Care Delivery Organizations (CDOs) across the United States with the goal of ensuring that the right molecular tests get to the right patients at the right time. If interested, please send CV to: [email protected]
